Publication details

Analýza moderních prognostických faktorů na buněčné a molekulární úrovni určujících riziko transformace monoklonální gamapatie nejasného významu do mnohočetného myelomu

Investor logo
Investor logo
Title in English Analysis of Modern Prognostic Factors on Cellular and Molecular Level Determining Risk of Transformation of Monoclonal Gammopathy of Undetermined Significance into Multiple Myeloma
Authors

ŘÍHOVÁ Lucie SANDECKÁ Viera KLINCOVÁ Mária VARMUŽOVÁ Tamara SUSKÁ Renata VŠIANSKÁ Pavla MIKULÁŠOVÁ Aneta SMETANA Jan GREŠLIKOVÁ Henrieta KUPSKÁ Renata NĚMEC Pavel BARTOŇOVÁ Jana KUGLÍK Petr PENKA Miroslav HÁJEK Roman

Year of publication 2012
Type Article in Periodical
Magazine / Source Klinická biochemie a metabolismus
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords monoclonal gammopathy of undetermined significance; multiple myeloma; prognosis; flow cytometry; chromosomal aberrations
Description The pilot statistical analysis of 314 MGUS subjects from Registry of Monoclonal Gammopathies (RMG) was done. Basic clinical data were used together with existing (type of monoclonal protein - MIG, level of MIG, serum free light chain ratio – FLC ratio) and new prognostic parameters (presence of cytogenetic abnormalities, flow cytometry enumeration of clonal plasma cells and presence of immunoparesis). Results: Higher number of plasma cells according to the morphology and presence of >95 % PC with aberrant phenotype CD19-CD56+/- as well were more frequently associated with transformation of MGUS into MM (p<0.05). Also, the presence of any immunoparesis and/or immunoparesis affecting both uninvolved immunoglobulins was more frequently detected in transformed MGUS (p=0.001). The first analysis of existing and new prognostic factors in MGUS achieved sensitivity of the stratification about 50 % within 2 years. Conclusion: The significance of morphological and flow cytometry assessment of PCs was confirmed and presence of the immunoparesis plays an important role as well. Model of stratification will be further developed with the aim of achieving 90 % sensitivity within 2 years and a similar analysis will be performed also for asymptomatic multiple myeloma (aMM).
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info